Patents by Inventor Robert Seid
Robert Seid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9248180Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: GrantFiled: April 22, 2014Date of Patent: February 2, 2016Assignee: Valneva Austria GmbHInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Publication number: 20150216967Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: ApplicationFiled: April 22, 2014Publication date: August 6, 2015Applicant: Valneva Austria GmbHInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Patent number: 8765148Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: GrantFiled: February 21, 2011Date of Patent: July 1, 2014Assignee: Valneva Austria GmbHInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Publication number: 20120308618Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.Type: ApplicationFiled: February 21, 2011Publication date: December 6, 2012Applicant: Intercell AGInventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
-
Patent number: 8293275Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.Type: GrantFiled: September 1, 2010Date of Patent: October 23, 2012Assignees: Med Immune, LLC, The Regents of the University of ColoradoInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Theodore W. Randolph, Robert Seid
-
Publication number: 20110243996Abstract: This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration.Type: ApplicationFiled: April 1, 2011Publication date: October 6, 2011Applicants: Medlmmune, LLC, The Regents of the University of ColoradoInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Patent number: 7923029Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.Type: GrantFiled: April 10, 2003Date of Patent: April 12, 2011Assignee: MedImmune LLCInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Publication number: 20100330162Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.Type: ApplicationFiled: September 1, 2010Publication date: December 30, 2010Applicants: Medlmmune, LLC, The Regents of the University of Colorado, a body corporationInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Publication number: 20070253984Abstract: The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.Type: ApplicationFiled: April 19, 2007Publication date: November 1, 2007Applicant: WyethInventors: Lakshmi Khandke, Ronald Malone, Xudong Yang, Hanyoung Han, Jee Look, Zhaowei Jin, Robert Seid, Ying Chen
-
Patent number: 7169392Abstract: The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: GrantFiled: August 19, 2003Date of Patent: January 30, 2007Assignee: Chiron SrlInventor: Robert Seid
-
Publication number: 20040052805Abstract: The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: ApplicationFiled: August 19, 2003Publication date: March 18, 2004Applicant: Chiron CorporationInventor: Robert Seid
-
Publication number: 20040042972Abstract: This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration.Type: ApplicationFiled: April 10, 2003Publication date: March 4, 2004Applicants: MedImmune Vaccines, inc., The Regents of the University of Colorado, a body corporate,Inventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Publication number: 20040042971Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.Type: ApplicationFiled: April 10, 2003Publication date: March 4, 2004Applicants: MedImmune Vaccines, Inc., The Regents of the University of Colorado, a Body Corporate, Boulder, CoInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Patent number: 6638513Abstract: The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: GrantFiled: August 7, 1997Date of Patent: October 28, 2003Assignee: Chiron S.r.l.Inventor: Robert Seid
-
Publication number: 20020034518Abstract: The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: ApplicationFiled: August 7, 1997Publication date: March 21, 2002Inventor: ROBERT SEID